Speculation of a buyout by Qiagen. Apparently that company’s CEO Thierry Bernard has been on the board for T2 Biosystems for several years.
Looks like the company would be a very good fit. The speculation about a possible buyout by Qiagen was that they were waiting to see if T2 Bio’s tests actually worked.
As all of them seem to work it looks like there’s some plausibility to the connection. As they say it’s a matter of joining the dots. Until anything is confirmed by either company all of this is unsubstantiated.
I like the chances more and more when I read certain posts over there on StockTwits.